Market closed
Cidara Therapeutics/$CDTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cidara Therapeutics
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Ticker
$CDTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
69
Website
CDTX Metrics
BasicAdvanced
$195M
-
-$23.94
0.98
-
Price and volume
Market cap
$195M
Beta
0.98
52-week high
$28.42
52-week low
$10.00
Average daily volume
111K
Financial strength
Current ratio
3.536
Quick ratio
2.911
Long term debt to equity
2.043
Total debt to equity
3.41
Management effectiveness
Return on assets (TTM)
-23.89%
Return on equity (TTM)
-200.46%
Valuation
Price to revenue (TTM)
2.016
Price to book
1.09
Price to tangible book (TTM)
1.09
Price to free cash flow (TTM)
-0.562
Growth
Revenue change (TTM)
44.48%
Earnings per share change (TTM)
168.65%
3-year revenue growth (CAGR)
-1.04%
3-year earnings per share growth (CAGR)
6.21%
What the Analysts think about CDTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cidara Therapeutics stock.
CDTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CDTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CDTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cidara Therapeutics stock?
Cidara Therapeutics (CDTX) has a market cap of $195M as of January 31, 2025.
What is the P/E ratio for Cidara Therapeutics stock?
The price to earnings (P/E) ratio for Cidara Therapeutics (CDTX) stock is 0 as of January 31, 2025.
Does Cidara Therapeutics stock pay dividends?
No, Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Cidara Therapeutics dividend payment date?
Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Cidara Therapeutics?
Cidara Therapeutics (CDTX) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.